| Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. | |
| | |
MedLine Citation:
|
PMID: 17014005 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Tumor necrosis factor-a (TNF-a) is a key cytokine in the pathogenesis of chronic inflammatory arthritides, has proatherogenic effects, and may be positively correlated with impairment of the action of insulin. Patients with chronic inflammatory arthritides have an increased risk for cardiovascular diseases. We assessed whether anti-TNF-a treatment modifies the unfavorable lipid profile induced by chronic inflammatory arthritides. METHODS: Sixty patients (24 with rheumatoid arthritis, 26 ankylosing spondylitis, and 10 psoriatic arthritis) receiving infliximab because of ongoing disease activity despite disease modifying drugs (DMARD) were prospectively studied for 6 months. Lipid profile, total cholesterol/high density lipoprotein cholesterol (TC/HDL-C), and low density lipoprotein cholesterol (LDL-C)/HDL-C ratios, as well as disease activity indices (DAS28 and BASDAI), were assessed. RESULTS: A sustained increase of serum HDL-C was observed [mean increase (95% CI)] 5 (3-7) mg/dl, 3.5 (1-6) mg/dl, and 3 (1-5) mg/dl at 1, 3, and 6 months, respectively (p < 0.01). Compared to nonresponders, HDL-C increased significantly more in EULAR or BASDAI responders (0.8 vs 5.8 mg/dl; p = 0.05). Serum TC was significantly increased [11 (4-8) mg/dl; p = 0.001] only after the first month of treatment. TC/HDL-C and LDL-C/HDL-C decreased only after the first month [0.3 (0.1-0.4), p < 0.01, and 0.2 (0.1-0.4), p < 0.01, respectively]. For patients with baseline LDL-C > 130 mg/dl, LDL-C/HDL-C decreased (p < 0.05) during the whole study period and TC/HDL-C decreased (p < 0.05) at 1 and 3 months. CONCLUSION: Anti-TNF-a treatment in patients with chronic inflammatory arthritides induces a modest, but sustained, increase in serum HDL-C levels, which may have a favorable effect in reducing the cardiovascular risk in these patients. |
| | |
Authors:
|
Elias Spanakis; Prodromos Sidiropoulos; John Papadakis; Emmanuel Ganotakis; George Katsikas; Stylianos Karvounaris; Argyro Bizaki; Heraklis Kritikos; Dimitrios T Boumpas |
Related Documents
:
|
8988945 - Relation of dietary carbohydrates to blood lipids in the special intervention and usual... 16896505 - Effect of red mold rice supplements on serum and meat cholesterol levels of broilers ch... 19229635 - Relationship between forgiveness and psychological and physiological indices in cardiac... 11126145 - The emerging role of hdl cholesterol. is it time to focus more energy on raising high-d... 22444415 - Early lysine deficiency in young broiler chicks. 12619805 - Growth performance of different breed crosses of chicks fed diets with different protei... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't Date: 2006-10-01 |
Journal Detail:
|
Title: The Journal of rheumatology Volume: 33 ISSN: 0315-162X ISO Abbreviation: J. Rheumatol. Publication Date: 2006 Dec |
Date Detail:
|
Created Date: 2006-12-04 Completed Date: 2007-03-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7501984 Medline TA: J Rheumatol Country: Canada |
Other Details:
|
Languages: eng Pagination: 2440-6 Citation Subset: IM |
Affiliation:
|
Department of Rheumatology, Clinical Immunology, and Allergy, University Hospital, Medical School, University of Crete, Heraklion, Greece. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antibodies, Monoclonal / therapeutic use* Antirheumatic Agents / therapeutic use* Arthritis / blood, drug therapy*, physiopathology Arthritis, Psoriatic / blood, drug therapy, physiopathology Arthritis, Rheumatoid / blood, drug therapy, physiopathology Cholesterol, HDL / blood, drug effects* Female Health Status Humans Male Middle Aged Prospective Studies Severity of Illness Index Spondylitis, Ankylosing / blood, drug therapy, physiopathology Treatment Outcome Tumor Necrosis Factor-alpha / antagonists & inhibitors*, immunology |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Cholesterol, HDL; 0/Tumor Necrosis Factor-alpha; 0/infliximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients.
Next Document: Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis.